Direct acting antivirals (DAAs) have fundamentally changed the treatment of hepatitis C virus (HCV) infection and reduced the discard rate of HCV-infected organs by offering a treatment option with a high likelihood of cure posttransplant. This has spurred increased interest in transplanting organs from HCV-positive donors into recipients both with and without
kidney transplant recipients. Due to a persistent organ supply/demand mismatch, access to transplant remains limited and waiting times unacceptably long for all organ types. Thus, the availability of DAAs has sparked interest in the transplant community in increasing use of organs from HCV (+) donors for both HCV-infected and HCV-uninfected recipients in an effort to decrease waiting times. In this chapter, we report general trends in transplant for HCV (+) donors and recipients for all solid organs, with particular emphasis on kidney and liver transplants. Nomenclature is important here. A donor who is anti-HCV (+) may or may not be infected. In general, approximately two-thirds of anti-HCV (+) donors are nucleic acid test (NAT) positive. A donor who is HCV NAT (+) is viremic and infectious. This increase began in 2014, coinciding with the arrival and expanded use of second-generation DAAs for HCV. Pancreas, heart, and lung transplant candidates showed parallel increases in willingness to accept organs from anti-HCV (+) donors, and approximately one-third of listed heart and lung candidates in 2018 consented to their use. Conversely, willingness to accept organs from anti-HCV (+) donors decreased among waitlisted liver and intestine transplant candidates. The proportion of willing liver transplant candidates declined from 48.3% in 2007 to a nadir of 20.7% in 2016 before increasing to 29.6% in 2018. Reasons for reduced interest among intestine and liver candidates are unclear, but we speculate that they might relate to shorter waiting times for intestine transplants compared with waiting times for other organs and concern about potentially infecting liver transplant recipients with HCV. Willingness to accept an organ from an anti-HCV (+) donor varied substantially across transplant programs, donation service areas (DSAs), Organ Procurement and Transplantation Network (OPTN) regions, and states. Geographic heat maps displaying adult waitlisted candidate willingness to accept anti-HCV 
Kidney
Some areas across the US report high willingness to accept anti-HCV (+) kidneys (Ohio, Michigan, Illinois, New York, Arizona, Oregon, and portions of the central and southeastern United States). Among OPTN regions, willingness to accept ranged from 2.7% to 30.1% in 2018. In 2018, 27 transplant programs reported that more than 50% of waitlisted candidates were willing to accept an anti-HCV (+) kidney. Across all programs, willingness ranged from 0% to 100%, and was more common in 2017 -2018 than in 2007 -2008 . Even across Department of Veterans Affairs transplant programs, willingness patterns were heterogeneous, ranging from 67.8% to 0%. Program kidney transplant volume had at best only a weak correlation with willingness to accept an anti-HCV (+) kidney, depending on year.
Characteristics of adult waitlisted candidates willing to accept anti-HCV (+) donor kidneys are shown in Table HEP 1. Given that a primary benefit of accepting an anti-HCV (+) kidney is substantially reduced waiting time, candidates with long anticipated waiting times, for example due to blood type or minimal accrued waiting time, would theoretically derive the most benefit from accepting anti-HCV (+) kidneys. As expected, kidney transplant candidates willing to accept anti-HCV (+) kidneys were more likely to have waited less than 1 year (76.9% vs. 55.0%), to be pre-dialysis (21.9% vs. 18.6%) or have less than 3 years of dialysis time (73.5% vs. 60.1%), to be of black race (39.2% vs. 30.1%), or to have blood type B (15.9% vs. 15.3%) or O (51.0% vs. 49.9%), compared with unwilling candidates.
Liver
Liver transplant programs reported candidate willingness to accept anti-HCV (+) donor livers ranging from 0% to 100% in 2018. Willingness to accept was less common in 2017-2018 than in 2007 -2008 . Variability was substantial across DSAs and OPTN regions, similar to variability in willingness to accept anti-HCV (+) kidneys. These observations suggest that willingness to accept an anti-HCV (+) kidney or liver is not dependent on geographic location but is heavily influenced by the particular transplant program where candidates are listed.
Fewer differences were noted between liver transplant candidates willing and unwilling to accept anti-HCV (+) organs than among kidney transplant candidates (Table HEP 2 ). Willing candidates were more likely to be aged older than 50 years (83.0% vs. 76.0%) or to be of black race (10.3% vs. 7.5%). In contrast to kidney candidates, there was virtually no difference in willingness to accept by ABO blood type. A greater proportion of unwilling candidates had model for end-stage liver disease scores 35 or higher, compared with willing candidates (14.2% vs. 12.1%). 
Kidney
Kidney transplants using anti-HCV (+) donors have steadily increased since 2014, from 290 that year to 977 in 2018. Similarly kidney transplants using HCV NAT (+) donors also increased, from 275 in 2015 to 570 in 2018; 59.2% of HCV NAT (+) kidneys in 2018 were transplanted into HCV (-) recipients. While use of kidneys from HCV (+) donors is increasing, transplants of these organs still comprise a small fraction of all kidney transplants performed each year. In 2018, 6.9% and 4.0% of all kidney transplants were from anti-HCV (+) and NAT (+) donors, respectively. From 2016 to 2018, nationally 1151 donor anti-HCV (+) to recipient anti-HCV (+) (D+/R+) and 979 donor anti-HCV (+) to recipient anti-HCV (-) (D+/R-) kidney transplants were performed. Only 58% of anti-HCV (+) kidney donors in 2018 were NAT (+) and truly infected, illustrating the importance of using NAT instead of anti-HCV when classifying donors. The number of HCV NAT (+) donor to anti-HCV (-) recipient kidney transplants also increased across most OPTN regions, even from 2017 to 2018. ( The states with the highest use of anti-HCV (+) kidneys were California, Florida, Maryland, New York, Ohio, Pennsylvania, and Tennessee, each of which transplanted over 100 such kidneys from 2016 to 2018. Conversely, 15 states performed 10 or fewer kidney transplants using anti-HCV (+) donors. Geographic variation in prevalence of HCV infection in the US may account for this geographic difference in use of anti-HCV (+) kidneys. State-level variation in HCV infection prevalence may also explain the imperfect correlation between percentages of programs willing to accept HCV (+) kidneys and actual numbers of anti-HCV (+) donor kidney transplants performed. Transplant programs located in states with low prevalence of HCV infection likely receive fewer anti-HCV (+) offers than programs in states with high prevalence, regardless of how many waitlisted candidates have agreed to receive an HCV (+) kidney.
Liver
Although the proportion of patients willing to accept anti-HCV (+) livers had decreased until recently, the number of liver transplants using anti-HCV (+) or NAT (+) donors actually increased, with a sharp rise in 2015 similar to that seen for anti-HCV (+) kidneys. In 2018, 644 liver transplants were performed from anti-HCV (+) donors, compared with 308 in 2014. A total of 418 liver transplants used HCV NAT (+) donors in 2018, compared with 236 in 2015 (Figure HEP 19, Figure HEP 20) .
From 2016 to 2018, a total of 1272 D+/R+ liver transplants were performed ( Figure HEP 28 ), the highest numbers in California, Maryland, New York, Ohio, and Pennsylvania. As with kidneys, reported willingness to accept an anti-HCV (+) liver did not necessarily correlate with the number of anti-HCV (+) donor liver transplants performed. Less common were the 458 D+/R-liver transplants performed between 2016 and 2018.
Lung/Heart
Lung and heart transplants using anti-HCV (+) donors have been much less common than kidney and liver transplants, and almost never performed in the pre-DAA era except under extraordinary circumstances. Prior to 2016, only 11 anti-HCV (+) donor heart transplants and 5 anti-HCV (+) donor lung transplants were performed. Although heart and lung transplant programs have increased their use of anti-HCV (+) and HCV NAT (+) donors in recent years, the increase began in 2017, later than at kidney and liver programs. Given that so few lung and heart transplants using anti-HCV (+) donors have been performed, trends in geographic variation are not yet evident.
4 Allograft survival using anti-HCV (+) organs
Kidney
Studies conducted prior to the availability of DAAs indicated that transplanting kidneys from anti-HCV (+) donors was associated with worse allograft outcomes compared with transplanting kidneys from HCV (-) donors. Data from recipients who underwent transplant in 2013 appear to support these reports. Although early allograft survival of anti-HCV (+) donor allografts was similar or even slightly better than survival of anti-HCV (-) donor allografts (95.1% vs. 93.3% at 1 year), 5-year allograft survival was worse (73.3% vs. 79.1%) in an unadjusted analysis ( Figure HEP 29) . When stratified by donor and recipient hepatitis status, 1-year allograft survival for anti-HCV (-) recipients who received anti-HCV (+) donor organs again was better than for other donor/recipient pairings (D+/R+ 94.9% vs. D+/R-96.2% vs. D-/R+ 89.9% vs. D-/R-93.5%) in an unadjusted analysis, but 5-year allograft survival was worse (D+/R+ 74.1% vs. D+/R-69.2% vs. D-/R+ 74.1% vs. D-/R-79.4%) ( Figure HEP 30 ). However, these transplants occurred during the infancy of the DAA era. The majority of these patients were likely not treated for their HCV infection or were treated several years after the transplant, and the well-described adverse effects of chronic HCV infection posttransplant likely contributed to the worse long-term allograft survival.
Data from transplant recipients in 2016 to 2017, which more likely reflect current practice and stratify donors by NAT status so viremic donors are identified, show better 1-year unadjusted allograft survival for D+/R-kidney trans-plant recipients than for the other pairings, similar to the 2013 data (D+/R-95.8% vs. D-/R-94.7% vs. D+/R+ 93.5% vs. D-/R+ 93.6%) ( Figure HEP 31 ). Allograft survival was worst for HCV-infected recipients, regardless of donor HCV status, which may suggest that the recipient's HCV status is more important than the donor's. Data regarding which NAT (+) donor kidney transplant recipients were treated with DAAs posttransplant are not available in the SRTR database; however, most were likely treated with DAAs. It is plausible that long-term allograft survival will be better for patients undergoing transplant in the post-DAA era than for the older cohort, but this should be closely monitored.
Liver
In an unadjusted analysis, 5-year allograft survival was slightly worse for patients who received a liver from an anti-HCV (+) donor than for those who received a liver from an anti-HCV (-) donor in 2013 (74.9% vs. 76.7%), and 1-year allograft survival was slightly better (90.7% vs. 89.1%) ( Figure HEP 32) . Using a more recent cohort of recipients from 2013 to 2017, the 1-year unadjusted allograft survival differential increased to 92.2% vs. 89.9% for donor anti-HCV (+) vs. donor anti-HCV (-). When the same cohort was stratified by donor/recipient grouping, 1-year unadjusted allograft survival was better for HCV-infected recipients who received an anti-HCV (+) liver than for the other pairings (D+/R+ 92.5% vs. D+/R-89.9% vs. D-/R-89.8% vs. D-/R+ 89.8%) ( Figure HEP 33) . Overall, unadjusted allograft survival was better at 1 year for 2017 liver transplants from HCV NAT (+) donors than from uninfected donors (92.3% vs. 91.1%). The highest unadjusted 1-year allograft survival was for HCV NAT (+) donor to HCV NAT (-) recipient in 2017 (D+/R-94.6% vs. D+/R+ 93.4% vs. D-/R+ 91.1% vs D-/R-90.4%), but these data are limited, as few D+/R-transplants were performed ( Figure HEP 34) . Differences in donor and recipient factors likely affected the observed allograft survival; adjusting for these characteristics is an important future investigation.
Conclusion
In the past few years, waitlisted candidates across all organ types except intestine have been more willing to accept organs from anti-HCV (+) donors, and use of anti-HCV (+) donors has increased across kidney, heart, lung, and liver transplant. Both of these observations are likely due to the increasing availability of DAAs, which have been shown to be highly effective in curing HCV infection. Short-term kidney and liver allograft survival in recipients of anti-HCV (+) organs is similar to that in recipients of anti-HCV (-) organs in unadjusted analyses. While long-term HCV (+) allograft outcomes are yet to be determined, increasing use of these organs, including NAT (+) organs, increases the pool of available organs and improves access for all candidates awaiting a life-saving transplant. This publication lists non-federal resources in order to provide additional information to consumers. The views and content in these resources have not been formally approved by the U.S. Department of Health and Human Services (HHS) or the Health Resources and Services Administration (HRSA). Neither HHS nor HRSA endorses the products or services of the listed resources.
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